Physicians’ Opinions Survey on FDA’s Bydureon Approval

2012-03-06
Published : Mar-2012

Physicians were asked to assess their impressions of Bydureon in terms of efficacy, safety, tolerability, expected use, and other important factors. Key questions are broken down by specialty or familiarity to highlight difference in physician perceptions

Highlights

Datamonitor anticipates that the initial enthusiasm will ultimately be muted once physicians gain experience with the drug. Nevertheless, a once-weekly antidiabetic agent clearly represents an attractive option for type 2 diabetes patients, and physicians expect the drug to be a welcome addition to their armamentarium.

FDA’s Bydureon Approval

Published: February 2012
Price
: Single User License US$3800            Corporate User License – US$9500

                    Request Sample


Your key questions answered
  • Assess physicians’ opinions of Bydureon as compared with Amylin’s twice-daily Byetta (exenatide) and Novo Nordisk’s once-daily Victoza (liraglutide)
  • Determine physicians’ expectations for Bydureon’s uptake, line of therapy, and use in combination with other antidiabetics
  • Evaluate how Bydureon may expand the overall market for GLP-1 agonists

Table of Contents

BYDUREON FDA APPROVAL: PHYSICIAN OPINION
Background

SURVEY RESULTS
Demographics
Limited familiarity with PCPs could present a marketing challenge
Impressions of Bydureon’s efficacy differ based on familiarity
Tolerability issues trump safety concerns among physicians familiar with Bydureon
High expectations for Bydureon use will likely come down with increased experience
Endocrinologists expect to use Bydureon in earlier line of therapy compared to PCPs
Combination use with oral antidiabetics is likely
Physicians expect Bydureon to expand the GLP-1 agonist market
Conclusion

APPENDIX
Report methodology
Datamonitor consulting

Disclaimer

List of Figures

Figure: On average, how many patients with type 2 diabetes do you treat per month?
Figure: How familiar are you with Bydureon (once-weekly exenatide)?
Figure: For each attribute below, please select the one drug that you would prefer to prescribe, based on performance (or predicted performance) on that attribute
Figure: Please select the one drug that you would prefer to prescribe, based on efficacy (HbA1c lowering ability)
Figure: Please rank the following potential safety (and tolerability) issues you are most concerned about with Bydureon on a scale of 1 to 7, where 1 is the issue of greatest concern and 7 is the issue of least concern
Figure: Please select the one drug that you would prefer to prescribe, based on injection device
Figure: Where in the treatment algorithm do you think you will most commonly prescribe Bydureon?
Figure: Please consider your hypothetical Bydureon-treated patient population a year post-launch. What percentage of the Bydureon-treated patient population do you expect to have previously been treated with each of the following options?
Figure: Please choose up to three drug classes with which Bydureon could be used in combination. If there are more than three classes, please select the three most likely
Figure: Please give your opinion on how the introduction of Bydureon, and any other market trends, will impact on the number of patients on GLP-1 agonists in the US

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
More Reports
Title Price Buy Now

EpiCast Report: Growth Hormone Deficiency – Epidemiology Forecast to 2026

EpiCast Report: Growth Hormone Deficiency - Epidemiology Forecast to 2026 Summary GHD is an endocrine disorder characterized by the insufficient production of GH by the pituitary gland (CGF, 2003). The ICD-10 Clinical Modification (ICD-10-CM) code for GHD is E23.0. GHD is more commonly seen in children, although it can develop during adulthood. GHD can be present from birth, in which case it is known as congenital, or it can be secondary due to brain trauma and is known as acquired. The signs and symptoms of the disease can vary. Generally, a child with GHD is born with normal size at birth, but has delayed rates of bone development and bone lengthening later on. GHD in children affects growth and development. In the 7MM, the diagnosed prevalent cases of GHD for all ages and both sexes ......
$3995

EpiCast Report: Venous Thromboembolism – Epidemiology Forecast to 2026

EpiCast Report: Venous Thromboembolism - Epidemiology Forecast to 2026 Summary Venous thromboembolism (VTE), which is composed of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a blood clot (thrombosis) of the circulatory system that leads to impeded blood flow, which can have serious consequences in the affected individual (Heit, 2015). In VTE, a DVT is a clot that occurs only in the veins; generally, they occur in the deep veins of the legs and pelvis, but may also occur in the veins of the upper body (AHA, 2017; Cohen et al., 2007; Heit, 2015). The clot may break off from its original location and travel throughout the circulatory system, and if the clot ends up in the lung, it is known as a PE (AHA, 2017). Our epidemiologists forecast an increase in the diagnosed inciden......
$3995

Chlamydia Tests – Medical Devices Pipeline Assessment, 2017

Chlamydia Tests - Medical Devices Pipeline Assessment, 2017 Summary GlobalData's Medical Devices sector report, "Chlamydia Tests - Medical Devices Pipeline Assessment, 2017" provides an overview of Chlamydia Tests currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Chlamydia Tests pipeline products. This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team o......
$2500

Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in 2016. The report portrays detailed comparative data on the number of deals and their value in the last five years, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the......
$3500

Top Trends in Healthcare and OTC 2017: Exploring OTC medication, vitamins, minerals and supplements; functional food and drink; and sports nutrition categories

Global consumers are becoming more health-conscious as a reaction to rising obesity levels and lifestyle-related illnesses, such as diabetes, in the modern world. Consumers' busy lives are a major driver for the healthcare and OTC market as people opt for more convenient, multifunctional, and personalized products that better target their specific needs. Over-the-counter (OTC) drugs are those sold directly to a consumer without a prescription from a healthcare professional, as compared to prescription drugs, which may be sold only to consumers possessing a valid prescription. The pressures of modern life are taking their toll on consumers as their increasingly hectic lifestyles, due to work, active social lives and family responsibilities, means that stress is the most concerning hea......
$3450

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2017 in Pharmaceuticals

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for March 2017 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in March 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry. Data prese......
$1000

Underground Gas Storage Industry Outlook in Europe to 2021: Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Storage Sites

Underground Gas Storage Industry Outlook in Europe to 2021: Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Storage Sites Summary "Underground Gas Storage Industry Outlook in Europe to 2021: Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Storage Sites", is a comprehensive report on underground gas storage industry in Europe. The report provides gas storage site details such as asset name, operator name, storage type, start year, working gas capacity along with withdrawal rate for all active and planned gas storage assets in the region. The report also provides key country comparisons based on contribution to working gas capacity. The report also provides capital expenditure outlook by key countries, year on year, ......
$5000

Underground Gas Storage Industry Outlook in North America to 2021: Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Storage Sites

Underground Gas Storage Industry Outlook in North America to 2021: Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Storage Sites Summary "Underground Gas Storage Industry Outlook in North America to 2021: Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Storage Sites", is a comprehensive report on underground gas storage industry in North America. The report provides gas storage site details such as asset name, operator name, storage type, start year, working gas capacity along with withdrawal rate for all active and planned gas storage assets in the region. The report also provides key country comparisons based on contribution to working gas capacity. The report also provides capital expenditure outlook by key coun......
$5000

Underground Gas Storage Industry Outlook In Former Soviet Union To 2021: Capacity And Capital Expenditure Forecasts With Details Of All Operating And Planned Storage Sites

Underground Gas Storage Industry Outlook In Former Soviet Union To 2021: Capacity And Capital Expenditure Forecasts With Details Of All Operating And Planned Storage Sites Summary "Underground Gas Storage Industry Outlook In Former Soviet Union To 2021: Capacity And Capital Expenditure Forecasts With Details Of All Operating And Planned Storage Sites", is a comprehensive report on underground gas storage industry in Former Soviet Union. The report provides gas storage site details such as asset name, operator name, storage type, start year, working gas capacity along with withdrawal rate for all active and planned gas storage assets in the region. The report also provides key country comparisons based on contribution to working gas capacity. The report also provides capital expenditure o......
$5000

Gas Processing Industry Outlook in Europe to 2021: Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Processing Plants

Gas Processing Industry Outlook in Europe to 2021: Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Processing Plants Summary "Gas Processing Industry Outlook in Europe to 2021: Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Processing Plants", is a comprehensive report on gas processing industry in Europe. The report provides gas processing plant details such as name, operator name, type, start year, process/conditioning methods and gas processing capacity for active and planned gas processing plants in the region. The report also provides key country comparisons based on contribution to processing capacity. The report also provides capital expenditure outlook by key countries, year on year, from 2017 to 2021. Pla......
$5000